Dr. Anjali Anil Bharne, M.D Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1200 Garden View Rd, Suite 200, Encinitas, CA 92024 Phone: 760-536-7700 Fax: 760-536-7710 |
Laurie Frakes, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 477 N El Camino Real, Ste D200, Encinitas, CA 92024 Phone: 760-452-3340 Fax: 760-452-3344 |
Dr. Rae Davis Felthouse, M.D. Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 2240 Encinitas Blvd, D402, Encinitas, CA 92024 Phone: 760-815-7853 Fax: 858-756-5018 |
Dr. Tresa Mcgranahan, M.D., PH.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 326 Santa Fe Dr, Encinitas, CA 92024 Phone: 760-633-7032 |
Dallas Rose Lawry, DNP, FNP-C Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1200 Garden View Rd, Encinitas, CA 92024 Phone: 760-536-7700 Fax: 760-536-7698 |
News Archive
A team led by Duke Health scientists has identified a cellular process that could lead to the development of safer and more effective vaccines that protect pregnant women as well as their newborns from dangerous infections.
Researchers at The University of Texas M. D. Anderson Cancer Center and the National Cancer Institute have found that an experimental vaccine can prime the immune system to help fight an aggressive form of lymphoma, even though prior therapy had eliminated virtually all of the B cells thought necessary to mount such a defense.
Data from a long-term care facility in the USA indicate that a dedicated palliative care consult service results in a more favorable course of treatment and clinical outcomes for residents.
Nymox Pharmaceutical Corporation announced today its financial results for the second quarter of 2010. Nymox reported a net loss of $1,745,798, or $0.05 per share for the quarter and $3,015,348, or $0.10 per share for the six months ending June 30, 2010, compared to $1,220,152, or $0.04 per share for the quarter and $2,224,411, or $0.07 per share for the six months ending June 30, 2009. Net losses include stock compensation charges for the quarter of $245,245 in 2010 and $248,886 in 2009 and for the six months ending June 30 of $440,465 in 2010 and $558,536 in 2009.
› Verified 3 days ago